Company Encyclopedia
View More
name
Lantern Pharma
LTRN.US
Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers.
1.946 T
LTRN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors

    Lantern Pharma Inc. reported positive results from its Phase 1a study of LP-184 in advanced solid tumors, showing durable disease control in patients with DDR pathway deficiencies. The study met safety and tolerability endpoints, and Lantern plans to advance LP-184 into Phase 1b/2 trials.

    rttnews·
    US
    LTRN
    +6.50%
    rttnews·
    US
    LTRN
    +6.50%

    Lantern Pharma’s Earnings Call: Progress and Funding Needs

    Lantern Pharma's Q3 earnings call highlighted significant progress in clinical trials, regulatory advancements, and AI platform commercialization. Key achievements include the successful LP-184 Phase Ia trial and productive FDA meetings. The company maintains $12.4 million in cash, supporting operations into Q3 2026, but acknowledges the need for additional funding. Despite a net loss of $4.2 million, Lantern Pharma is optimistic about leveraging its AI platform for future growth, targeting a $7 billion market opportunity. The call conveyed a balance of achievement and the necessity for further funding to sustain growth.

    Tip Ranks·
    US
    LTRN
    +6.50%
    Tip Ranks·
    US
    LTRN
    +6.50%

    Lantern Pharma posts Q3 net loss of $4.2 million as LP-184 trial meets primary endpoints

    Lantern Pharma Inc. reported a Q3 2025 net loss of $4.2 million, down from $4.5 million in Q3 2024. Net loss per share was $0.39, down from $0.42. Operating expenses decreased to $4.3 million from $5.2 million. Cash and equivalents totaled $12.4 million, down from $24.0 million. Key developments included successful Phase 1a trial for LP-184, advancing LP-284 trials, and progress in Starlight Therapeutics and RADR AI platform.

    Reuters·
    US
    LTRN
    +6.50%
    Reuters·
    US
    LTRN
    +6.50%

    Lantern Pharma Achieves Key Milestones in Q3 2025

    Lantern Pharma reported its Q3 2025 financial results, achieving key milestones in clinical validation and regulatory advancements. The company met all primary endpoints in its LP-184 Phase 1a trial, received FDA guidance for a pediatric CNS cancer trial, and demonstrated commercial readiness of its AI platform. Despite zero revenue and cash flow concerns, analysts rate LTRN stock as a Buy with a $25 target, though technical sentiment signals a Strong Sell. Lantern Pharma focuses on AI-driven oncology drug development.

    Tip Ranks·
    US
    LTRN
    +6.50%
    Tip Ranks·
    US
    LTRN
    +6.50%

    Lantern Pharma | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    LTRN
    +6.50%
    LB filings·
    US
    LTRN
    +6.50%
    © 2025 Longbridge｜Disclaimer